Preclinical investigations using [(177)Lu]Lu-Ibu-DAB-PSMA toward its clinical translation for radioligand therapy of prostate cancer

[(177)Lu]Lu-Ibu-DAB-PSMA was previously characterized with moderate albumin-binding properties enabling high tumor accumulation but reasonably low retention in the blood. The aim of this study was to investigate [(177)Lu]Lu-Ibu-DAB-PSMA in preclinical in vivo experiments and compare its therapeutic...

Descripción completa

Detalles Bibliográficos
Autores principales: Tschan, Viviane J., Borgna, Francesca, Busslinger, Sarah D., Stirn, Martina, Rodriguez, Josep M. Monné, Bernhardt, Peter, Schibli, Roger, Müller, Cristina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9399046/
https://www.ncbi.nlm.nih.gov/pubmed/35635566
http://dx.doi.org/10.1007/s00259-022-05837-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9399046/
https://www.ncbi.nlm.nih.gov/pubmed/35635566
http://dx.doi.org/10.1007/s00259-022-05837-2

Ejemplares similares